Laura Kohtamäki

Laura Kohtamäki

Auto-generated profile, based on publicly available information

Laura Kohtamäki

Department of Oncology, Helsinki University Hospital, Comprehensive Cancer Center, University of Helsinki, Finland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
HKHenna Kasanen
Henna Kasanen
MHMicaela Hernberg
Micaela Hernberg
SMSiru Mäkelä
Siru Mäkelä
OBOscar Brück
Oscar Brück
SJSusanna Juteau
Susanna Juteau
AKAnna Kreutzman
Anna Kreutzman
Anti-PD1 treatment has improved the survival of metastatic melanoma patients, yet it is unknown which patients benefit from the treatment. In this exploratory study, we aimed to understand the effects of anti-PD1 therapy on the patients’ immune system and discover the characteristics that would result in successful treatment. We collected peripheral blood (PB) samples from 17 immuno-oncology-naïve metastatic melanoma patients before and after 1 and 3 months of anti-PD1 therapy. In addition, matching tumor biopsies at the time of diagnosis were collected for tissue microarray. The complete blood counts, PB immunophenotype, serum cytokine profiles, and tumor-infiltrating lymphocytes were analyzed and correlated with the clinical data. Patients were categorized based on their disease control into responders (complete response, partial response, stable disease > 6 months, N = 11) and non-responders (progressive disease, stable disease ≤ 6 months, N = 6). During therapy, the PB natural killer T (NKT) cell frequency, expression of CD25 and CD45RO on cytotoxic natural killer (NK) cells, and serum CXC chemokine levels were significantly increased in responders. Furthermore, higher age together with age-associated characteristics from PB, lower frequency of PB-naïve CD8+ T cells, and elevated levels of serum MCP-4 and OPG were discovered as baseline predictors of treatment response. We therefore propose that in addition to T cells, anti-PD1 treatment is associated with NK- and NKT-cell population dynamics, and that the age-associated characteristics from PB together with older age may contribute to prolonged PFS in anti-PD1-treated melanoma patients.

31 January 2020 in Acta Oncologica
Verified
Journal Article
Closed access
SMSiru Mäkelä
Siru Mäkelä
LKLaura Kohtamäki
Laura Kohtamäki
MLMarjut Laukka
Marjut Laukka
SJSusanna Juteau
Susanna Juteau
MHMicaela Hernberg
Micaela Hernberg
Purpose: To date, no clinical study has reported on the optimal treatment duration of PD-1 blockade in patients with metastatic melanoma. Worldwide, concern has been expressed that due to the high cost of anti-PD-1 therapy, it is not available for all patients. After approval of anti-PD-1 therapy as a first-line treatment, the Helsinki University Hospital institutional board for new drugs decided to treat the first patient cohort within a limited treatment duration program in order to offer this treatment to as many patients as possible. Patients and methods: The first 40 patients with metastatic melanoma initiating treatment at Helsinki University Hospital were to be treated within a six months maximum limited duration program. Patient follow-up was systematic according to a prospectively planned treatment protocol to enable evaluation of treatment efficacy and the safety of this treatment approach. Results: Thirty-eight patients were treated within the program. Seventeen out of these 38 patients completed the six-month regimen. Five discontinued treatment early due to toxicity, and 16 discontinued due to progressive disease. The response rate (RR) for all patients was 39%, but only 33% of these responses are ongoing. Median progression-free survival (PFS) for patients who completed the six-month therapy was 12 months (range, two to 44 months), and median overall survival (OS) has not yet been reached. Conclusions: Although RR is comparable to published data, the response duration is shorter. Based on our results, limiting treatment to only six months may increase the risk of shortening response duration.

24 November 2021 in Translational Oncology
Verified
Journal Article
Open access
LKLaura Kohtamäki
Laura Kohtamäki
MAMariliina Arjama
Mariliina Arjama
SMSiru Mäkelä
Siru Mäkelä
PIPhilipp Ianevski
Philipp Ianevski
KVKatja Välimäki
Katja Välimäki
MHMicaela Hernberg
Micaela Hernberg
• We established patient-derived cancer cell (PDC) lines from NRAS-positive MM tumors. • We carried out high-throughput drug testing with PDCs against 527 oncology drugs. • PDCs were sensitive to PI3K, mTOR, PLK1, MEK, ERK, and RAF inhibitors. • Drug combination synergies were identified. • Our results support application of PDCs for functional drug testing.

28 September 2019 in Acta Oncologica
Verified
Journal Article
Closed access
MKMattila Ensio Kalle
Mattila Ensio Kalle
PVPia Vihinen
Pia Vihinen
SRSusan Ramadan
Susan Ramadan
TSTanja Skyttä
Tanja Skyttä
LTLeena Tiainen
Leena Tiainen
MHMicaela Hernberg
Micaela Hernberg
(2019). Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. Acta Oncologica. Ahead of Print.

5 March 2021 in Melanoma Research
Verified
Journal Article
Closed access
LKLaura M. Kohtamäki
Laura M. Kohtamäki
MHMicaela Hernberg
Micaela Hernberg
MJMarjut Jaakkola
Marjut Jaakkola
SMSiru Mäkelä
Siru Mäkelä
Although new compounds have improved the treatment landscape of metastatic melanoma, very limited data exist on the efficacy and safety of treating older patients with novel agents. Here, we provide results of BRAF (BRAFi) ± MEK (MEKi) inhibitor treatment in patients over 75 years (oldest-old patients) with metastatic melanoma. Between 2011 and 2020, 34 consecutive patients with metastatic melanoma over 75 years of age (range 75–89) were treated with BRAFi ± MEKi at the Comprehensive Cancer Center of Helsinki University Hospital. Data on clinical and histopathological features, toxicity, response rate (RR), progression-free survival (PFS) and overall survival (OS) were collected. Patients were treated with BRAFi (n = 22) or BRAFi in combination with MEK inhibitor (MEKi) (n = 12). Grade 1–2 adverse events occurred in 68% of the patients, 32% had grade 3 adverse effects, dose reductions were made for 41% of patients and 29% terminated treatment due to toxicity. Overall, the RR was 62%. Complete responses were achieved in 27% of the patients, and 35% had partial responses. The median PFS was 8 months (range 0–57), and the median OS was 15 months (range 0–71). Tailored BRAFi ± MEKi treatment for older patients is feasible. Adverse effects occur frequently but are manageable by dose adjustment. The occurrence of toxicity of monotherapy was similar to that of combination therapy. The RR and median OS from our retrospective study are comparable with those reported in clinical trials and combination therapy produced somewhat more and longer-lasting responses. Hence, it seems that older patients may benefit from BRAFi treatment.

25 August 2023 in Acta Oncologica
Verified
Journal Article
Closed access
LKLaura Kohtamäki
Laura Kohtamäki
SLSuvi-Katri Leivonen
Suvi-Katri Leivonen
SMSiru Mäkelä
Siru Mäkelä
SJSusanna Juteau
Susanna Juteau
SLSirpa Leppä
Sirpa Leppä
MHMicaela Hernberg
Micaela Hernberg